Tuberculosis (TB) is the leading cause of death from an infectious bacterial disease. Poor diagnostic tools to detect active disease plague TB control programs and affect patient care.
Several groups, including ours, have observed that modified trehalose analogs, including fluorine- (14, 15) , azide-(16), alkyne- (17) or fluorophore-functionalized derivatives (14) , can be metabolically incorporated into the mycobacterial outer membrane as trehalose mycolates. The process is enabled by the promiscuity of Mtb's trehalose metabolic machinery, most prominently the antigen 85 complex (Ag85) that catalyzes mycolylation of trehalose (18) (Fig. 1A) . Since trehalose mycolates are unique to the Corynebacterineae suborder, which includes pathogenic mycobacteria and corynebacteria but not canonical Gram-positive or negative organisms nor human hosts, the use of trehalose analogs for clinical detection of Mtb is an intriguing proposition. Indeed, fluorinated trehalose analogs have potential application for PET imaging of lung-resident Mtb (19, 20) . Likewise, we considered the possible use of fluorescent trehalose analogs for detection of viable Mtb as for point-of-care sputum smear tests, but the requirement for removing unmetabolized probe to eliminate background fluorescence proved to be a major impediment (vide infra). A trehalose probe whose fluorescence signal is specifically activated by metabolic incorporation into the mycomembrane would overcome such a limitation.
Here we show that trehalose conjugated to the solvatochromic dye 4-N,N-dimethylamino-1,8-napthalimide (DMN), a reagent we call DMN-Tre, is metabolically incorporated into mycomembranes and enables fluorescent detection of mycobacteria in TB patient sputum samples. Unlike the classic ZN and auramine stains, DMN-Tre selectively labels live Mtb cells and this labeling is reduced by exposure to frontline TB drugs. This operationally simple method requires a single incubation step, with no washes, and may therefore powerfully complement current methods for TB diagnosis at the point of care.
We chose the environmentally-sensitive DMN dye based on work by Imperiali and coworkers' observation that the molecule exhibits a dramatic fluorescence turn-on when transitioned from aqueous to organic solvents (21-23). Accordingly, we reasoned that metabolic mycolylation of a DMN-trehalose conjugate (DMN-Tre, 1, Fig. 1B ) and subsequent integration into the hydrophobic mycomembrane would activate fluorescence and enable detection of live Mtb cells without need for washing away unmetabolized probe (Fig. 1A) . We synthesized DMN-Tre as well as two control compounds, DMN-glucose (DMN-Glc, 2, Fig. 1B ) and 6-fluorescein-trehalose (6-FlTre, 3, Fig. 1B ) (24) , and confirmed that DMN-Tre's fluorescence properties were similar with those reported for the free dye, including a ~700-fold enhancement in fluorescence intensity when dissolved in 99.9% dioxane versus water (Fig. 1C) .
To evaluate DMN-Tre's ability to label bacteria bearing mycomembranes, we tested These images were acquired by using standard FITC/GFP filter sets, but an even brighter image can be obtained by excitation at 405 nm, closer to DMN's excitation maximum (Fig. S3 ).
Next we performed a time course to determine the labeling kinetics. Msmeg and C. glutamicum (Cg) harvested during their exponential growth phase were incubated as above and imaged at various time points. As shown in Fig. 2B , labeling was already visible at the first time point -5 min for Msmeg and 3 min for Cg. While Cg showed even cell surface labeling by the earliest time point analyzed, Msmeg showed fluorescence only at the polar regions, consistent with the polar growth model (14) . This signal diffused across the cell length so that by 1 hour, Msmeg cells were uniformly labeled.
We performed a series of controls to confirm that DMN-Tre labeling results from metabolic conversion to trehalose mycolates within the mycomembrane rather than nonspecific insertion into the mycomembrane. DMN-Glc, which possesses the same dye but installed on glucose, did not label Msmeg, suggesting that the trehalose scaffold is key for the observed fluorescence signal from DMN-Tre treatment (Fig. S1A ). As well, DMN-Tre labeling was reduced in the presence of excess trehalose, suggesting competition in the same biosynthetic pathway (Fig. S1B) . We assessed DMN-Tre labeling of a panel of Msmeg trehalose transporter mutants ( Fig. S1C) (25) (26) (27) and found that DMN-Tre incorporation was comparable to wild-type, suggesting that labeling occurs primarily through the Ag85 pathway, consistent with previous studies (14, 17) . Accordingly, the Ag85 inhibitor ebselen (28) decreased DMN-Tre labeling of Msmeg cells in a dose-dependent manner (Fig. S1D) . Lastly, we analyzed purified glycolipids from DMN-Tre-labelled Cg by TLC (Fig. S2A ) and mass spectrometry (Fig. S2B-D) and directly detected DMN-Tre-derived monomycolates.
DMN-Tre's potential as a diagnostic tool for TB depends on its selectivity for mycobacteria among other bacterial species. We incubated canonical Gram-negative andpositive organisms (Escherichia coli, Staphylococcus aureus, Listeria monocytogenes and Bacillus subtilis) with DMN-Tre and, without any washing, observed no detectable labeling (Figs. 2C and S4 ). In the same experiment, Cg labeled brightly with DMN-Tre. This specificity is striking given the important role that free trehalose plays in these different bacterial species (29, 30) . Further, we combined mCherry-expressing Msmeg with these four bacterial species in a 1:10 mycobacteria/other bacteria ratio and incubated the mixture with both DAPI and DMN-Tre for one hour. We observed bright and specific labeling of only Msmeg (Fig. 2D) . Lastly, we evaluated labeling of slow-growing pathogenic Mtb with DMN-Tre. Although labeling occurred more slowly compared to the faster growing Msmeg, we observed fluorescent cells within a 2-hour incubation period (Fig. 2E ).
Current microscopy-based methods for TB diagnosis cannot distinguish live from dead mycobacteria. Given that DMN-Tre labeling depends on mycomembrane biosynthesis, we hypothesized that this method would be specific for live bacteria. Indeed, labeling was abrogated by heat killing Msmeg (Fig. 3A-B) . We also evaluated the effect of TB drug treatment on labeling. Msmeg treated for 3 hours with a cocktail of ethambutol, rifampicin, isoniazid and SQ109, each at a dose at or above reported MICs, lost all detectable labeling with DMN-Tre (Fig. 3C-D) . Similarly, drug-treated Mtb cells did not label with DMN-Tre (Fig. 3E, Fig. S5 ). In contrast, labeling with the commercial auramine-based mycobacterial staining dye (Fluorescent Stain Kit for Mycobacteria, Sigma-Aldrich cat. No. 05151) was unaffected by drug treatment (Fig. 3F) .
To gain insight into the potential clinical utility of DMN-Tre, we sought to detect Mtb cells in TB-positive patient sputum samples. We obtained overnight sputum samples from 4 patients who were TB positive by either smear microscopy, GeneXpert or mycobacterial culture.
The samples were decontaminated using a standard NaOH treatment, centrifuged to remove debris, and then incubated with DMN-Tre overnight (Fig. 4A) . Fluorescent Mtb cells were readily apparent in all samples (Figs. 4B and S6 ).
The World Health Organization has articulated the urgent need for new sputum tests for rapid TB diagnosis, particularly those that can report on drug susceptibility (2) . Our data suggest that DMN-Tre labeling might fulfill this purpose. The method specifically targets a pathway in mycomembrane biosynthesis and therefore reports both on bacterial identity and vitality. DMNTre's unique mode of fluorescence activation allows for an operationally simple procedure -a single incubation step. Notably, we found DMN-Tre to be very stable on the bench or in shipping containers for weeks at room temperature, and even in aqueous solution at 37 °C. Thus, DMN-Tre labeling holds much promise as reagent for TB research and diagnosis in low-resource settings. 
